Effectiveness of Immunotherapy on COVID-19

COVID-19 is an infection triggered by a recently discovered coronavirus, SARS-CoV-2. COVID-19 patients experience respiratory illnesses, including difficulty breathing, pneumonia, cough, etc. People also suffer from body aches and extreme weakness. Sp02 level becomes significantly less, leading to worsening of the disease. Many people have lost their lives due to corona becoming a pandemic. After many investigations, a vaccine against this virus has been discovered, which reduces the infection. Still, vaccinated people also have chances of getting an infection, but the severity of symptoms gets reduced to much extent. It was found that novel vaccine technology used in the COVID-19 vaccine can prevent up to 95% of infections. Immunotherapy plays a significant role in fighting against infection. According to studies, hematology patients are more prone to suffer from an infection. The macrophages, neutrophils, and dendritic cells help in reducing the infection. There are mainly two types of vaccine discovered against coronavirus disease –

Covaxin

Covishield

Covaxin is 78% - 100% effective whereas Covishield is 70% - 90% effective.

Clinical studies are used to assess vaccine effectiveness. After receiving the corona disease vaccine, several adverse side effects may arise. Vaccines rescue the breaths of millions of diseased beings with viruses and bacteria. We celebrate the advances made and the highpoint challenges ahead in vaccinations and the science underlying them as the world waits for safe and effective COVID-19 vaccines. We outlined the current prospective therapeutic methods for disorders caused by COVID-19 infection, as well as their mechanisms of action, safety, and efficacy, in this study.